- Home
- DX vs ADPT Comparison
DX vs ADPT Comparison
Compare DX & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DX
- ADPT
- Stock Information
- Founded
- DX 1987
- ADPT 2009
- Country
- DX United States
- ADPT United States
- Employees
- DX N/A
- ADPT N/A
- Industry
- DX Real Estate Investment Trusts
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DX Real Estate
- ADPT Health Care
- Exchange
- DX Nasdaq
- ADPT Nasdaq
- Market Cap
- DX 1.6B
- ADPT 1.8B
- IPO Year
- DX N/A
- ADPT 2019
- Fundamental
- Price
- DX $12.37
- ADPT $13.77
- Analyst Decision
- DX Buy
- ADPT Strong Buy
- Analyst Count
- DX 4
- ADPT 8
- Target Price
- DX $13.00
- ADPT $12.38
- AVG Volume (30 Days)
- DX 4.6M
- ADPT 1.7M
- Earning Date
- DX 10-20-2025
- ADPT 11-06-2025
- Dividend Yield
- DX 16.48%
- ADPT N/A
- EPS Growth
- DX 592.83
- ADPT N/A
- EPS
- DX 0.63
- ADPT N/A
- Revenue
- DX $107,764,000.00
- ADPT $205,216,000.00
- Revenue This Year
- DX N/A
- ADPT $32.76
- Revenue Next Year
- DX $70.80
- ADPT $15.81
- P/E Ratio
- DX $19.72
- ADPT N/A
- Revenue Growth
- DX 119.64
- ADPT 21.60
- 52 Week Low
- DX $10.79
- ADPT $3.98
- 52 Week High
- DX $14.52
- ADPT $13.78
- Technical
- Relative Strength Index (RSI)
- DX 42.68
- ADPT 61.65
- Support Level
- DX $12.32
- ADPT $12.59
- Resistance Level
- DX $12.59
- ADPT $13.68
- Average True Range (ATR)
- DX 0.19
- ADPT 0.67
- MACD
- DX -0.04
- ADPT -0.01
- Stochastic Oscillator
- DX 6.94
- ADPT 98.62
About DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including, residential MBS and commercial MBS.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).